Avatar of admin


Supreme Court Says Human Genes Cannot Be Patented, Striking Down Breast and Ovarian Cancer Gene Patents

June 13, 2013 in Blogs

By Steven Rosenfeld, AlterNet

The Court's unanimous decision is a major public-interest victory.

Human genetic sequences cannot be patented, the U.S. Supreme Court ruled Thursday in an unexpected decision that is a tremendous public interest victory.

“Myriad [Genetics] did not create anything,” the Supreme Court held, in a lawsuit that challenged the firm’s monopoly on two gene sequences used in expensive tests that reveal whether women have an inherited risk of breast and ovarian cancer. “To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.”

The immediate impact gives other biotech firms the go-ahead to develop less-expensive DNA-based tests for the genetic risk of breast and ovarian cancer. Looking down the road, the ruling will force biotech companies to rethink their business models that have been based on ‘owning’ the building blocks of life.

“The Court rightfully found that patents cannot be awarded for something so fundamental to nature as DNA,” said Daniel B. Ravicher, Executive Director of the Public Patent Foundation, which lead the suit challenging two patents awarded for gene sequences tied to breast and ovarian cancer. “Bottom line, diagnostic genetic testing is now free from any patent threat, forever, and the poor can now have their genes tested as freely as the rich.”

Women’s health care advocates immediately hailed the Court’s decision, saying it put patients' health and scientific research ahead of private corporate profits.

“This ruling makes a huge and immediate difference to those with a known and suspected inherited risk of breast cancer,” said Karuna Kagger, executive director of Breast Cancer Action. “It is a tremendous victory for all people everywhere. The Supreme Court has taken a significant stand to limit the rights of companies to own human genes by striking down Myriad’s monopoly.”

“The Court struck down a major barrier to patient care and medical innovation,” said Sandra Park, senior staff attorney with the ACLU Women’s Rights Project, which was a co-counsel in the lawsuit. “Myriad did not invent the BCRA [breast and ovarian cancer] genes and should not control them.”

The public interest attorneys challenged …read more


Leave a reply

You must be logged in to post a comment.